Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK.

JCI Insight. 2018 Jul 25;3(14). pii: 120422. doi: 10.1172/jci.insight.120422. [Epub ahead of print]

2.

BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Ozer HG, El-Gamal D, Powell B, Hing ZA, Blachly JS, Harrington B, Mitchell S, Grieselhuber NR, Williams K, Lai TH, Alinari L, Baiocchi RA, Brinton L, Baskin E, Cannon M, Beaver L, Goettl VM, Lucas DM, Woyach JA, Sampath D, Lehman AM, Yu L, Zhang J, Ma Y, Zhang Y, Spevak W, Shi S, Severson P, Shellooe R, Carias H, Tsang G, Dong K, Ewing T, Marimuthu A, Tantoy C, Walters J, Sanftner L, Rezaei H, Nespi M, Matusow B, Habets G, Ibrahim P, Zhang C, Mathé EA, Bollag G, Byrd JC, Lapalombella R.

Cancer Discov. 2018 Apr;8(4):458-477. doi: 10.1158/2159-8290.CD-17-0902. Epub 2018 Jan 31.

PMID:
29386193
3.

RAF inhibitors that evade paradoxical MAPK pathway activation.

Zhang C, Spevak W, Zhang Y, Burton EA, Ma Y, Habets G, Zhang J, Lin J, Ewing T, Matusow B, Tsang G, Marimuthu A, Cho H, Wu G, Wang W, Fong D, Nguyen H, Shi S, Womack P, Nespi M, Shellooe R, Carias H, Powell B, Light E, Sanftner L, Walters J, Tsai J, West BL, Visor G, Rezaei H, Lin PS, Nolop K, Ibrahim PN, Hirth P, Bollag G.

Nature. 2015 Oct 22;526(7574):583-6. doi: 10.1038/nature14982. Epub 2015 Oct 14.

PMID:
26466569
4.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI, Keedy VL, Singh AS, Puzanov I, Kwak EL, Wagner AJ, Von Hoff DD, Weiss GJ, Ramanathan RK, Zhang J, Habets G, Zhang Y, Burton EA, Visor G, Sanftner L, Severson P, Nguyen H, Kim MJ, Marimuthu A, Tsang G, Shellooe R, Gee C, West BL, Hirth P, Nolop K, van de Rijn M, Hsu HH, Peterfy C, Lin PS, Tong-Starksen S, Bollag G.

N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366.

5.

Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer.

Thompson ML, Jimenez-Andrade JM, Chartier S, Tsai J, Burton EA, Habets G, Lin PS, West BL, Mantyh PW.

Pain. 2015 Sep;156(9):1692-702. doi: 10.1097/j.pain.0000000000000228.

6.

Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

Smith CC, Zhang C, Lin KC, Lasater EA, Zhang Y, Massi E, Damon LE, Pendleton M, Bashir A, Sebra R, Perl A, Kasarskis A, Shellooe R, Tsang G, Carias H, Powell B, Burton EA, Matusow B, Zhang J, Spevak W, Ibrahim PN, Le MH, Hsu HH, Habets G, West BL, Bollag G, Shah NP.

Cancer Discov. 2015 Jun;5(6):668-79. doi: 10.1158/2159-8290.CD-15-0060. Epub 2015 Apr 6.

7.

Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor.

Zhang C, Ibrahim PN, Zhang J, Burton EA, Habets G, Zhang Y, Powell B, West BL, Matusow B, Tsang G, Shellooe R, Carias H, Nguyen H, Marimuthu A, Zhang KY, Oh A, Bremer R, Hurt CR, Artis DR, Wu G, Nespi M, Spevak W, Lin P, Nolop K, Hirth P, Tesch GH, Bollag G.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5689-94. doi: 10.1073/pnas.1219457110. Epub 2013 Mar 14.

8.

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R.

N Engl J Med. 2012 Jan 19;366(3):207-15. doi: 10.1056/NEJMoa1105358.

9.

Interrogating the kinome.

Zhang C, Habets G, Bollag G.

Nat Biotechnol. 2011 Nov 8;29(11):981-3. doi: 10.1038/nbt.2021. No abstract available.

PMID:
22068532
10.

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K.

Nature. 2010 Sep 30;467(7315):596-9. doi: 10.1038/nature09454.

11.

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent.

Artis DR, Lin JJ, Zhang C, Wang W, Mehra U, Perreault M, Erbe D, Krupka HI, England BP, Arnold J, Plotnikov AN, Marimuthu A, Nguyen H, Will S, Signaevsky M, Kral J, Cantwell J, Settachatgull C, Yan DS, Fong D, Oh A, Shi S, Womack P, Powell B, Habets G, West BL, Zhang KY, Milburn MV, Vlasuk GP, Hirth KP, Nolop K, Bollag G, Ibrahim PN, Tobin JF.

Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):262-7. doi: 10.1073/pnas.0811325106. Epub 2008 Dec 30.

12.

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.

Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3041-6. doi: 10.1073/pnas.0711741105. Epub 2008 Feb 19.

13.

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.

O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F.

Cancer Cell. 2004 Dec;6(6):611-23.

14.

cDNA array analyses of K-ras-induced gene transcription.

Habets GG, Knepper M, Sumortin J, Choi YJ, Sasazuki T, Shirasawa S, Bollag G.

Methods Enzymol. 2001;332:245-60. No abstract available.

PMID:
11305101
15.

Activation of Rac1 by human Tiam1.

Bollag G, Crompton AM, Peverly-Mitchell D, Habets GG, Symons M.

Methods Enzymol. 2000;325:51-61. No abstract available.

PMID:
11036591
16.

Role of Tiam 1 in Rac-mediated signal transduction pathways.

Collard JG, Habets GG, Michiels F, Stam J, van der Kammen RA, van Leeuwen F.

Curr Top Microbiol Immunol. 1996;213 ( Pt 2):253-65. Review. No abstract available.

PMID:
9053294
17.

Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells.

van Leeuwen FN, van der Kammen RA, Habets GG, Collard JG.

Oncogene. 1995 Dec 7;11(11):2215-21.

PMID:
8570171
18.

A role for Rac in Tiam1-induced membrane ruffling and invasion.

Michiels F, Habets GG, Stam JC, van der Kammen RA, Collard JG.

Nature. 1995 May 25;375(6529):338-40.

PMID:
7753201
19.

Sequence of the human invasion-inducing TIAM1 gene, its conservation in evolution and its expression in tumor cell lines of different tissue origin.

Habets GG, van der Kammen RA, Stam JC, Michiels F, Collard JG.

Oncogene. 1995 Apr 6;10(7):1371-6.

PMID:
7731688
20.

The invasion-inducing TIAM1 gene maps to human chromosome band 21q22 and mouse chromosome 16.

Habets GG, van der Kammen RA, Jenkins NA, Gilbert DJ, Copeland NG, Hagemeijer A, Collard JG.

Cytogenet Cell Genet. 1995;70(1-2):48-51.

PMID:
7736788
21.

Identification of an invasion-inducing gene, Tiam-1, that encodes a protein with homology to GDP-GTP exchangers for Rho-like proteins.

Habets GG, Scholtes EH, Zuydgeest D, van der Kammen RA, Stam JC, Berns A, Collard JG.

Cell. 1994 May 20;77(4):537-49.

PMID:
7999144
22.
23.

Sublocalization of an invasion-inducing locus and other genes on human chromosome 7.

Habets GG, van der Kammen RA, Willemsen V, Balemans M, Wiegant J, Collard JG.

Cytogenet Cell Genet. 1992;60(3-4):200-5.

PMID:
1505215
24.

Allele-specific detection of K-ras oncogene expression in human non-small-cell lung carcinomas.

Slebos RJ, Habets GG, Evers SG, Mooi WJ, Rodenhuis S.

Int J Cancer. 1991 Apr 22;48(1):51-6.

PMID:
1850383
25.

Induction of invasive and metastatic potential in mouse T-lymphoma cells (BW5147) by treatment with 5-azacytidine.

Habets GG, van der Kammen RA, Scholtes EH, Collard JG.

Clin Exp Metastasis. 1990 Nov-Dec;8(6):567-77.

PMID:
1699692
26.

Genetic analysis of T-lymphoma invasion and metastasis.

Collard JG, Habets GG, Vander Kammen R, Scholtes E, Stoopen G.

Pathol Biol (Paris). 1989 Nov;37(9):1030-1. No abstract available.

PMID:
2608329
27.

Nuclear protein factors and erythroid transcription of the human A gamma-globin gene.

Catala F, deBoer E, Habets G, Grosveld F.

Nucleic Acids Res. 1989 May 25;17(10):3811-27.

28.

Genetic basis of T-lymphoma invasion.

Collard JG, Habets GG, van der Kammen R, Scholtes E.

Invasion Metastasis. 1989;9(6):379-90. Review.

PMID:
2689385
29.
30.

Genetic analysis of invasion and metastasis.

Collard JG, Roos E, La Rivière G, Habets GG.

Cancer Surv. 1988;7(4):691-710. Review.

PMID:
3072071

Supplemental Content

Loading ...
Support Center